Pejman Abbasi Pashaki, Kiarash Shirbandi, Sina Ramezani, F. Rahim, Z. Jamalpoor
{"title":"SARS-Cov2-Induced Cytokine Storm and Schizophrenia, Could There be a Connection?","authors":"Pejman Abbasi Pashaki, Kiarash Shirbandi, Sina Ramezani, F. Rahim, Z. Jamalpoor","doi":"10.20471/may.2022.58.01.12","DOIUrl":null,"url":null,"abstract":"Today, a new coronavirus (2019-nCoV, later named SARS-CoV-2) has become known as a pandemic with over 3,949,200 cases and 271,782 deaths. It has been considered that most of the deaths in infected patients stem from co-morbidity conditions. Therefore, understanding at-risk populations are currently under the focus of investigations. This object has highly driven attention to put patients with a higher potential of death related to SARS-CoV2 infection at priority. For instance, this can happen in Schizophrenia owing to ambiguous immunology attributes, including elevated levels of pro-inflammatory cytokines and stress-related immune disability. Given that, the hyper-inflammatory responses are the significant cause of the pathophysiology of the SARS-CoV2-related mortality. Moreover, SARS-CoV2 can prompt the risk of developing Schizophrenia in the future. This review punctuates that prenatal/perinatal infection could be associated with increased Schizophrenia risk;on the flip side, the potential risk of ongoing medication can worsen mentally disabled patients, and healthy people are at risk.","PeriodicalId":8294,"journal":{"name":"Archives of Psychiatry Research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Psychiatry Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20471/may.2022.58.01.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Today, a new coronavirus (2019-nCoV, later named SARS-CoV-2) has become known as a pandemic with over 3,949,200 cases and 271,782 deaths. It has been considered that most of the deaths in infected patients stem from co-morbidity conditions. Therefore, understanding at-risk populations are currently under the focus of investigations. This object has highly driven attention to put patients with a higher potential of death related to SARS-CoV2 infection at priority. For instance, this can happen in Schizophrenia owing to ambiguous immunology attributes, including elevated levels of pro-inflammatory cytokines and stress-related immune disability. Given that, the hyper-inflammatory responses are the significant cause of the pathophysiology of the SARS-CoV2-related mortality. Moreover, SARS-CoV2 can prompt the risk of developing Schizophrenia in the future. This review punctuates that prenatal/perinatal infection could be associated with increased Schizophrenia risk;on the flip side, the potential risk of ongoing medication can worsen mentally disabled patients, and healthy people are at risk.